Clinical trials data
Delayed Recall Module in dementia and Alzheimer's trials: 71 registered studies
Every registered dementia and Alzheimer's disease study on ClinicalTrials.gov that names Delayed Recall Module in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered dementia and Alzheimer's disease studies name it in an outcome measure
- 71
- Name it in a primary outcome, 24%
- 17 of 71
Tests named in the same studies
- 1
Cancellation Test31 studies, 6 as a primary outcome
- 2
Category Fluency16 studies, 3 as a primary outcome
- 3
Verbal Fluency14 studies, 1 as a primary outcome
- 4
Symbol Coding12 studies, 3 as a primary outcome
- 5
Trail Making Test10 studies, 5 as a primary outcome
- 6
Digit Span Test8 studies, 2 as a primary outcome
- 7
Short Story Recall7 studies, 2 as a primary outcome
- 8
Picture Naming Test5 studies, 2 as a primary outcome
- 9
Selective Reminding Task5 studies, 0 as a primary outcome
- 10
Free Recall Task4 studies, 2 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 1 | 0 |
| 2005 | 1 | 1 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 2 | 0 |
| 2009 | 2 | 1 |
| 2010 | 2 | 1 |
| 2011 | 3 | 0 |
| 2012 | 5 | 2 |
| 2013 | 1 | 1 |
| 2014 | 3 | 2 |
| 2015 | 4 | 1 |
| 2016 | 6 | 2 |
| 2017 | 7 | 1 |
| 2018 | 5 | 0 |
| 2019 | 2 | 0 |
| 2020 | 2 | 0 |
| 2021 | 9 | 1 |
| 2022 | 3 | 0 |
| 2023 | 2 | 2 |
| 2024 | 4 | 1 |
| 2025 | 4 | 1 |
| 2026 | 2 | 0 |
Phases and study sizes
By phase
- Early phase 11 studies, 0 as a primary outcome
- Phase 11 studies, 0 as a primary outcome
- Phase 1/23 studies, 0 as a primary outcome
- Phase 230 studies, 5 as a primary outcome
- Phase 2/33 studies, 3 as a primary outcome
- Phase 325 studies, 7 as a primary outcome
- Not applicable7 studies, 2 as a primary outcome
- Observational1 studies, 0 as a primary outcome
Participants per study
- Phase 2282 median, 85 to 359
- Phase 31,111 median, 760 to 1,643
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Phase 2 | 30 | 282 | 85 to 359 |
| Phase 3 | 25 | 1,111 | 760 to 1,643 |
When dementia and Alzheimer's trials measure it
Latest time point of each outcome
- Within a day1 outcomes, 0 as a primary outcome
- Up to 4 weeks3 outcomes, 1 as a primary outcome
- 1 to 3 months5 outcomes, 2 as a primary outcome
- 3 to 6 months13 outcomes, 4 as a primary outcome
- 6 to 12 months9 outcomes, 1 as a primary outcome
- 1 to 2 years35 outcomes, 8 as a primary outcome
- Over 2 years5 outcomes, 1 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
71 of the 71 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting5 studies, 0 as a primary outcome
- Not yet recruiting1 studies, 0 as a primary outcome
- Active, not recruiting6 studies, 3 as a primary outcome
- Completed35 studies, 7 as a primary outcome
- Stopped early22 studies, 7 as a primary outcome
- Status unknown2 studies, 0 as a primary outcome
What they test
- Behavioral1 studies, 0 as a primary outcome
- Drug58 studies, 13 as a primary outcome
- Device2 studies, 1 as a primary outcome
- Dietary supplement4 studies, 0 as a primary outcome
- Procedure1 studies, 0 as a primary outcome
- Biological5 studies, 1 as a primary outcome
- Other9 studies, 3 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States59 studies, 16 as a primary outcome
- Canada39 studies, 7 as a primary outcome
- Spain34 studies, 9 as a primary outcome
- Germany30 studies, 9 as a primary outcome
- Japan30 studies, 6 as a primary outcome
- France28 studies, 7 as a primary outcome
- United Kingdom28 studies, 8 as a primary outcome
- Australia27 studies, 4 as a primary outcome
- Italy25 studies, 4 as a primary outcome
- Poland24 studies, 5 as a primary outcome
- Sweden18 studies, 2 as a primary outcome
- South Korea17 studies, 3 as a primary outcome
51 countries in all. A study with sites in several counts in each; 1 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed dementia and Alzheimer's disease studies that name Delayed Recall Module: 32 of 35, 91%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed dementia and Alzheimer's disease studies that name Delayed Recall Module | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 20, 57% | 776, 10% |
| Results on ClinicalTrials.gov only | 7, 20% | 1,139, 14% |
| A results paper only | 5, 14% | 1,711, 22% |
| Neither | 3, 9% | 4,327, 54% |
The 71 studies
71 studies match. 17 name Delayed Recall Module in a primary outcome. Median size 327 participants. Median time to the primary outcome: 14 months.
Loading 71 studies; the filters turn on when they arrive.
2026 is partly planned starts.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 1 | 0 |
| 2005 | 1 | 1 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 2 | 0 |
| 2009 | 2 | 1 |
| 2010 | 2 | 1 |
| 2011 | 3 | 0 |
| 2012 | 5 | 2 |
| 2013 | 1 | 1 |
| 2014 | 3 | 2 |
| 2015 | 4 | 1 |
| 2016 | 6 | 2 |
| 2017 | 7 | 1 |
| 2018 | 5 | 0 |
| 2019 | 2 | 0 |
| 2020 | 2 | 0 |
| 2021 | 9 | 1 |
| 2022 | 3 | 0 |
| 2023 | 2 | 2 |
| 2024 | 4 | 1 |
| 2025 | 4 | 1 |
| 2026 | 2 | 0 |
Library tests named most
Conditions
Phases
Participants
Lead sponsor: industry 54, NIH 1, other 16. Interventional 70, observational 1.
As a primary outcomeSecondary or other outcomeDelayed Recall Module
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07842146 | Start2026 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Mild cognitive impairment | Participants60 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07642726 | Start2018 | PhaseObservational | ConditionsDementia and Alzheimer's, Aging, frailty and exercise | Participants276 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07392723 | Start2025 | PhasePhase 2 | ConditionsDementia and Alzheimer's, Aging, frailty and exercise | Participants20 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07385937 | Start2026 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Mild cognitive impairment | Participants150 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07251023 | Start2025 | PhasePhase 3 | ConditionsDementia and Alzheimer's | Participants450 | Lead sponsorIndustry | StatusRecruiting | Library tests named
|
| NCT07033494 | Start2025 | PhasePhase 2 | ConditionsDementia and Alzheimer's | Participants340 | Lead sponsorIndustry | StatusRecruiting | Library tests named
|
| NCT06709014 | Start2025 | PhasePhase 3 | ConditionsDementia and Alzheimer's | Participants760 | Lead sponsorIndustry | StatusActive, not recruiting | Library tests named
|
| NCT06538116 | Start2024 | PhasePhase 2 | ConditionsDementia and Alzheimer's | Participants304 | Lead sponsorIndustry | StatusCompleted | Library tests named
|
| NCT06335173 | Start2024 | PhasePhase 2 | ConditionsDementia and Alzheimer's | Participants542 | Lead sponsorIndustry | StatusActive, not recruiting | Library tests named
|
| NCT06223360 | Start2024 | PhasePhase 2 | ConditionsDementia and Alzheimer's | Participants406 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT06112639 | Start2024 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Mild cognitive impairment, Multiple sclerosis, Cancer | Participants192 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT05771428 | Start2023 | PhasePhase 2 | ConditionsDementia and Alzheimer's | Participants263 | Lead sponsorIndustry | StatusCompleted | Library tests named
|
| NCT05532657 | Start2023 | PhasePhase 3 | ConditionsDementia and Alzheimer's, Mild cognitive impairment, Aging, frailty and exercise, Hearing loss | Participants629 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT05399888 | Start2022 | PhasePhase 2 | ConditionsDementia and Alzheimer's, Mild cognitive impairment | Participants416 | Lead sponsorIndustry | StatusActive, not recruiting | Library tests named
|
| NCT05310071 | Start2022 | PhasePhase 3 | ConditionsDementia and Alzheimer's | Participants1,027 | Lead sponsorIndustry | StatusStopped early | Library tests named
|
| NCT05143528 | Start2022 | PhasePhase 3 | ConditionsDementia and Alzheimer's | Participants1,275 | Lead sponsorIndustry | StatusStatus unknown | Library tests named
|
| NCT05063539 | Start2021 | PhasePhase 2 | ConditionsDementia and Alzheimer's | Participants327 | Lead sponsorIndustry | StatusCompleted | Library tests named
|
| NCT04997681 | Start2021 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Mild cognitive impairment | Participants60 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT04777396 | Start2021 | PhasePhase 3 | ConditionsDementia and Alzheimer's | Participants1,840 | Lead sponsorIndustry | StatusCompleted | Library tests named
|
| NCT04770220 | Start2021 | PhasePhase 3 | ConditionsDementia and Alzheimer's | Participants325 | Lead sponsorIndustry | StatusCompleted | Library tests named
|
| NCT04640077 | Start2020 | PhasePhase 2 | ConditionsDementia and Alzheimer's | Participants95 | Lead sponsorIndustry | StatusCompleted | Library tests named
|
| NCT04619420 | Start2021 | PhasePhase 2 | ConditionsDementia and Alzheimer's | Participants523 | Lead sponsorIndustry | StatusStopped early | Library tests named
|
| NCT04592874 | Start2021 | PhasePhase 2 | ConditionsDementia and Alzheimer's | Participants356 | Lead sponsorIndustry | StatusCompleted | Library tests named
|
| NCT04437511 | Start2020 | PhasePhase 3 | ConditionsDementia and Alzheimer's | Participants1,736 | Lead sponsorIndustry | StatusActive, not recruiting ResultsPaper 1Paper 2Paper 3Paper 4Paper 5Paper 6Paper 7Paper 8Paper 9Paper 10Paper 11Paper 12Paper 13 | Library tests named
|
| NCT04421014 | Start2021 | PhaseNot applicable | ConditionsDementia and Alzheimer's, Obesity and diabetes | Participants99 | Lead sponsorNIH | StatusCompleted | Library tests named
|
Questions, answered from the data
How many dementia and Alzheimer's trials use Delayed Recall Module?
71 registered dementia and Alzheimer's disease studies on ClinicalTrials.gov name it in an outcome measure, 17 of them in a primary outcome: 4% of the condition's 1,673 studies with a cognitive outcome, against 1% of all of them. It is the 11th most named test in dementia and Alzheimer's trials.
Which tests do dementia and Alzheimer's trials use with Delayed Recall Module?
The Cancellation Test (31 studies), Category Fluency (16 studies) and Verbal Fluency (14 studies).
How many participants do phase 2 dementia and Alzheimer's trials that use Delayed Recall Module enroll?
Half of the phase 2 studies that name it enroll 282 participants or fewer, and the middle half enroll 85 to 359. 30 of them give a size.
When do dementia and Alzheimer's trials measure Delayed Recall Module?
Half of the primary outcomes that name Delayed Recall Module are measured within 14 months of the start, and the middle half from 6 months to 18 months. 17 primary outcomes give a duration.
How many completed dementia and Alzheimer's trials that use Delayed Recall Module have reported results?
32 of the 35 completed studies that name it, 91%, have reported results: 27 posted them on ClinicalTrials.gov, 25 have a results paper linked to the registry record, and 20 did both. The other 3 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
The census counts Delayed Recall Module and Week Later Game as one test family, so this page counts their studies together.
Run Delayed Recall Module in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.